---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-001328"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T14:25:20.160722+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# VolitionRx appoints Dr. Andrew Retter as Chief Medical Officer effective April 1, 2024

## Summary
- Dr. Retter is an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust, London, and dual-registered in Intensive Care and Haematology.
- He has advised Volition since January 2022 on Nu.Q® NETs, a CE-marked blood test for sepsis and NETosis-related diseases.
- As CMO, he will lead medical strategy and ensure clinical efforts are aligned with patient needs.

## SEC filing metadata
- accession: 0001477932-24-001328
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793224001328/0001477932-24-001328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793224001328/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-001328
- JSON: https://secwatch.observer/filing/0001477932-24-001328.json
- Plain text: https://secwatch.observer/filing/0001477932-24-001328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.